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Objective. CNS or peripheral nervous system dysfunction sometimes occurs in Henoch–Scho¨nlein patients.
Methods. We review all Henoch–Scho¨nlein cases published after 1969 with CNS dysfunction without severe hypertension and neuroimaging
studies (n¼ 35), cranial or peripheral neuropathy (n¼ 15), both CNS and peripheral nervous system dysfunction without severe hypertension
(n¼ 2) or nervous system dysfunction with severe hypertension (n¼ 2). Forty-four of the 54 patients were <20 years of age.
Results. In patients with CNS dysfunction without or with severe hypertension the following presentations were observed in decreasing order
of frequency: altered level of consciousness, convulsions, focal neurological deficits, visual abnormalities and verbal disability. Imaging
studies disclosed the following lesions: vascular lesions almost always involving two or more vessels, intracerebral haemorrhage, posterior
subcortical oedema, diffuse brain oedema and thrombosis of the superior sagittal sinus. Following lesions were noted in the subjects with
cranial or peripheral neuropathy without severe hypertension: peroneal neuropathy, peripheral facial palsy, Guillain–Barre´ syndrome, brachial
plexopathy, posterior tibial nerve neuropathy, femoral neuropathy, ulnar neuropathy and mononeuritis multiplex. Persisting signs of either
CNS (n¼ 9) or peripheral (n¼ 1) nervous system dysfunction were sometimes reported.
Conclusions. In Henoch–Scho¨nlein syndrome, signs of nervous system dysfunction are uncommon but clinically relevant. This review helps
clinicians managing Henoch–Scho¨nlein syndrome with nervous system dysfunction.
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Introduction
The characteristic clinical features of Henoch–Scho¨nlein syn-
drome, the most common vasculitis disorder of childhood, include
palpable purpura concentrated in dependent areas, arthralgia or
arthritis, abdominal pain and glomerulonephritis [1, 2].
Headache is rather common in this small vessel vasculitis [1, 2].
More rarely, Henoch–Scho¨nlein patients present with signs of
either CNS or peripheral nervous system dysfunction. Reports
available until the mid-seventies that deal with nervous system
involvement in Henoch–Scho¨nlein syndrome were aggregated by
French authors in two reviews [3, 4]. Since imaging is currently
integral to the diagnostic assessment of vasculitides affecting the
CNS [5], we performed an extensive review of the literature dealing
with nervous system dysfunction in Henoch–Scho¨nlein syndrome.
We included the patients with signs of CNS dysfunction, neuro-
imaging studies and those with cranial or peripheral neuropathy.
Materials and methods
Between November 2008 and April 2009, we performed a
thorough computer-based search of the terms anaphylactoid
purpura, Henoch, Henoch–Scho¨nlein, Scho¨nlein, Scho¨nlein–
Henoch, nervous system, vasculitis and angiitis in the US
National Library of Medicine database and in the web-based
search engine Google. Articles published after 1969 as full-
length articles or letters in peer-reviewed scientific literature
were considered. Pertinent secondary references were also
reviewed. Reports published in languages other than English,
French, German, Italian or Spanish were not included.
Using the above-mentioned research technique, we were able to
accumulate 37 cases of Henoch–Scho¨nlein syndrome with signs of
CNS dysfunction without severe arterial hypertension and CT or
MRI of the brain [6–42], which were published between 1983
and 2009. Henoch–Scho¨nlein patients with headache but without
any abnormal neurological signs were not included.
In two of the aforementioned 37 cases [12, 41], a concurrent
involvement of the peripheral nervous system was noted. In
15 further cases of Henoch–Scho¨nlein syndrome, which were
reported between 1970 and 2009, a cranial or peripheral
neuropathy without severe hypertension and without any CNS
dysfunction was noted [9, 43–56].
Severe arterial hypertension, which is common in Henoch–
Scho¨nlein glomerulonephritis, may cause widespread brain
abnormalities or peripheral facial palsy [57, 58]. As a consequence,
two Henoch–Scho¨nlein children with blood pressure 5 (99th
percentile þ 5 mm Hg), signs of nervous system dysfunction and
MRI were analysed separately [59, 60].
The diagnosis of Henoch–Scho¨nlein syndrome was based on
the classical palpable purpuric rash in the presence of at least
one of the following [61]: diffuse abdominal pain, arthritis or
arthralgia or a pathological urinalysis. A biopsy showing pre-
dominant IgA deposition was performed in 31 (57%) of the
54 patients (7, 9, 10, 12, 14–16, 19, 20, 22, 23, 25, 26, 28, 29, 31,
32, 35, 37–39, 43–47, 50, 51, 53, 61 and 62): skin biopsy (n¼ 15),
renal biopsy (n¼ 11), both skin and renal biopsy (n¼ 5). Testing
for IgG ANCA was negative in 14 patients with this examination
(6, 8, 12, 19, 20, 25, 29, 32, 35, 43, 45, 51, 53, 54).
Of the 54 patients, 32 were male and 21 were female subjects
(information unavailable [52] in one case), ranging in age between
3 and 68 years. Forty-four (81%) of the patients were <20 years of
age (Fig. 1). They had been reported from the following conti-
nents: 24 from Europe (France, n¼ 3; Germany, n¼ 2; Italy, n¼ 6;
Portugal, n¼ 1; Romania, n¼ 1; Spain, n¼ 2; Switzerland, n¼ 1;
Turkey, n¼ 6; and UK, n¼ 2), 18 from Asia (India, n¼ 2; Iran
n¼ 1; Japan, n¼ 6; Korea, n¼ 4; Saudi Arabia, n¼ 1; Taiwan,
n¼ 3; and Thailand, n¼ 1), 10 from North America (Canada,
n¼ 2 and USA, n¼ 8) and each 1 from Africa (Morocco) and
Australia. The case of a patient with a peripheral neuropathy,
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complicating Henoch–Scho¨nlein syndrome reported within a case
series of patients affected by vasculitic peripheral neuropathy,
was not included due to scanty data available [62].
Results
CNS dysfunction without severe hypertension
In 31 (84%) of the 37 patients with CNS dysfunction without
severe hypertension, the corresponding signs appeared in subjects
concomitantly presenting the distinctive rash of Henoch–
Scho¨nlein syndrome. The diagnosis was more tricky in the
remaining six cases (16%), considering that four patients devel-
oped the rash from 10 h until 8 days [9, 11, 21, 40] after onset
of CNS symptoms. Furthermore, in two cases [27, 34], CNS
dysfunction developed in subjects with past history of Henoch–
Scho¨nlein syndrome but without any cutaneous, articular or renal
signs since 5, respectively, 9 years. Apart from headache, follow-
ing neurological presentations were observed (Table 1): altered
level of consciousness, convulsions, visual abnormalities
and verbal disability. Imaging (MRI in 17 and CT alone in the
remaining 19 patients) was normal in five patients (14%; three
patients with MRI and two with CT). Following anomalies were
disclosed in the remaining 32 (86%) patients: ischaemic vascular
lesions almost always involving two or more vessels, intracerebral
haemorrhages, diffuse (mainly posterior) brain oedema [21, 42]
or thrombosis of the superior sagittal sinus (Table 2 and Fig. 2).
A secondary deficiency of clotting factor XIII was disclosed in
three patients [24, 27, 29] and vitamin K-dependent factors in one
[16] (with concurrent intestinal involvement). Testing for aPL
antibodies was strongly positive in the patient with thrombosis
of the superior sagittal sinus [6], and in a patient with an extensive
infarction involving lenticular nucleus, caudate nucleus and
periopercular region [37], but was never performed in the
remaining patients with CNS dysfunction.
A large haemorrhage was drained surgically in three patients [7,
16, 34]. A 14-year-old boy with a strongly reduced activity of the
clotting factor XIII and a large haemorrhage penetrating the
left ventricle died in spite of emergency neurosurgery [29]. The
management was conservative in the remaining patients: parent-
eral steroids were used in almost all patients (n¼ 32; 86%),
sometimes (n¼ 6; 17%) in association with cyclophosphamide
(n¼ 2; 6%) [25, 32], AZA (n¼ 1; 3%) [26], plasmapheresis
(n¼ 2; 5%) [18, 39] or intravenous immune globulin (n¼ 1; 3%)
[35]. Clotting factor XIII was administered in two patients with a
reduced activity of this factor [24, 27]. Heparin, and, subsequently,
warfarin were used in the patient with thrombosis of the superior
sagittal sinus and positive testing for aPL antibodies [6].
Minor sequelae at follow-up, which was sometimes rather short
(43 months), were observed in eight patients (13, 16, 21, 24, 25,
36, 37, 41): visual field defects (n¼ 3), verbal disabilities
(n¼ 2), focal neurological deficits (n¼ 2) and partial epilepsy
(n¼ 1).
Nervous system dysfunction with severe hypertension
In two children [59, 60] with Henoch–Scho¨nlein glomerulonephri-
tis and severe arterial hypertension, who presented with headache,
decreased level of consciousness, visual changes and convulsions,
MRI disclosed a mainly posterior subcortical oedema. In both
patients, control of hypertension was followed by a full remission
of the CNS dysfunction.
Cranial or peripheral nervous system dysfunction without
severe hypertension
Signs of peripheral nervous system dysfunction appeared in
17 subjects concomitantly presenting the distinctive rash of
Henoch–Scho¨nlein syndrome. The lesions, which appear
in Table 1, included polyneuropathy, mononeuropathy or mono-
neuropathy multiplex. A secondary deficiency of the clotting
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FIG. 1. Age distribution in 54 Henoch–Scho¨nlein patients (32 male and 21 female
subjects; information unavailable in one case) with nervous system dysfunction.
TABLE 1. Clinical presentation in 54 Henoch–Scho¨nlein patients (32 male and
21 female subjects; information unavailable in one case) with neurological
involvement
Characteristics n (%)
CNS dysfunction without severe hypertenson
Altered level of consciousness
Glasgow coma scale 10–12 10 (19)
Glasgow coma scale 49 19 (35)
Convulsions
Partial 4 (7)
Generalized 18 (33)
Focal neurological deficits 14 (26)
Visual abnormalities 12 (22)
Verbal disability
Mild 2 (4)
Severe 3 (6)
Nervous system dysfunction with severe hypertension
Glasgow coma scale 49 2 (4)
Generalized convulsions 2 (4)
Visual abnormalities 1 (2)
Cranial or peripheral neuropathy without severe hypertension
Peripheral facial palsy 3 (6)
Guillain–Barre´ syndrome 3 (6)
Brachial plexopathy 3 (6)
Peroneal neuropathya 4 (7)
Posterior tibial nerve neuropathy 1 (2)
Femoral neuropathy 1 (2)
Ulnar neuropathy (bilateral) 1 (2)
Mononeuritis multiplexb 1 (2)
aBilateral in one case (testing for aPL antibodies was performed in one patient and found to be
normal [52]). bMedian, superficial peroneal and medial plantar nerve.
TABLE 2. Cerebral lesions detected by neuroimaging in 37 Henoch–Scho¨nlein
patients with CNS dysfunction but without severe arterial hypertension
n (%)
Normal neuroimaging 5 (14)
Ischaemic lesion
One-vessel disease 1a (3)
Two or more vessels disease 16 (43)
Intracerebral haemorrhage 11 (30)
Two or more vessels disease and haemorrhage 1 (3)
Diffuse brain oedema 2 (5)
Sagittal sinus thrombosis 1 (3)
aMiddle cerebral artery [36].
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factor XIII occurred in one patient [53]. The management was
expectative in all cases with the exception of intravenous
immune globulin, which was prescribed in each one patient with
Guillain–Barre´ syndrome [51] and brachial plexopathy [41].
A persisting nervous dysfunction was noted in an 11-year-old
boy with brachial neuropathy [41].
Renal disease and uncommon features
Nephrotic-range proteinuria, a marker of rather severe kidney
disease, was noted in 29 (54%) of the 54 patients with nervous
system dysfunction (Table 3). Further uncommon features
(Table 3), including severe gastroduodenal involvement (n¼ 2),
gastric and colonic ulcers (n¼ 1), abdominal wall haematoma
(n¼ 1), retroperitoneal haematoma (n¼ 1), pulmonary oedema
associated with retinal artery occlusion (n¼ 1), pericardial tampo-
nade (n¼ 1), pericardial tamponade associated with necrosis of
the small intestine (n¼ 1) and myocarditis (n¼ 1), were noted in
9 (17%) of the 54 patients.
Discussion
Although the long-term prognosis of Henoch–Scho¨nlein syn-
drome is almost entirely attributable to the kidney disease [1, 2],
some rare extrarenal features may produce substantial morbidity
and mortality. The present review indicates that in Henoch–
Scho¨nlein syndrome, a clinically relevant neurological disease is
very rare and mostly affects subjects with either a rather severe
kidney disease or uncommon features. However, in two case series
[52, 63], including 39 unselected children affected by Henoch–
Scho¨nlein syndrome with normal neurological examination
and blood pressure, headache was reported in 11 (28%) of
them. More importantly, transient electroencephalographic
abnormalities including focal or generalized slow wave activity,
sharp waves, focal attenuation of the voltage activity and
sometimes also paroxysmal activity occurred in 21 (55%) of the
39 cases, indicating that in Henoch–Scho¨nlein syndrome mild
cerebral involvement is the rule rather than the exception.
Similarly, clinically relevant pulmonary disease is exceptional in
this vasculitis. Nonetheless, the lung transfer for carbon monoxide
is altered in most Henoch–Scho¨nlein children [64].
CNS dysfunction without severe hypertension
Like in other cerebral vasculitides, in Henoch–Scho¨nlein patients
with cerebral involvement, neuroimaging characteristically
discloses ischaemic lesions secondary to vessel wall proliferation
with resultant luminal obliteration (or thrombotic occlusion) or
haemorrhages with or without secondary ischaemia to vessel wall
proliferation with rupture of necrotic walls [65–67].
Nervous system dysfunction with severe hypertension
Altered level of consciousness, visual changes, convulsions and
MRI studies disclosing a mainly posterior subcortical oedema,
currently designated as reversible posterior leucoencephalopathy
syndrome, characterize hypertensive encephalopathy [68, 69].
The present experience confirms that posterior leucoencephalo-
pathy sometimes occurs also in normotensive (or slightly hyper-
tensive) patients with cerebral vasculitis [68, 69].
Lower motor neuron facial palsy sometimes occurs in children
with severe arterial hypertension [59, 60]. As a consequence, in
Henoch–Scho¨nlein syndrome peripheral facial palsy may result
not only from a vasculitic neuropathy (see below) but also from
severe hypertension. However, peripheral facial palsy has so
far never been associated with severe hypertension in Henoch–
Scho¨nlein syndrome.
Cranial or peripheral nervous system dysfunction without
severe hypertension
Vasculitides may cause inflammation in the walls of the vasa
nervorum and induce critical ischaemia to nerves. However,
sometimes lesions may result from compression by haematoma
or localized oedema [58].
In Churg–Strauss syndrome, WG and microscopic polyangiitis,
the most common vasculitides that affect the peripheral nervous
system, the corresponding clinical patterns are mononeuritis
multiplex, polyneuropathy, radiculopathy and neural plexopathy
[55]. In Henoch–Scho¨nlein patients with peripheral or cranial
neuropathy, facial palsy, Guillain–Barre´ syndrome, brachial
plexopathy, peroneal neuropathy, posterior tibial nerve neuro-
pathy, femoral neuropathy and mononeuritis multiplex were
observed.
Diagnostic work up
Generally, there is little diagnostic doubt in a subject with acute
CNS or peripheral nervous system dysfunction concurrently
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FIG. 2. Ischaemic or haemorrhagic vascular lesions detected by neuroimaging
in 29 patients with Henoch–Scho¨nlein syndrome and CNS dysfunction, but without
severe arterial hypertension.
TABLE 3. Severe kidney disease and uncommon features in 32 (59%) of the 54
Henoch–Scho¨nlein patients with nervous system dysfunction
Nephrotic-
range
proteinuria
Uncommon
features Totala
CNS dysfunction 19 7 20
Peripheral nervous system dysfunction 8 2 10
CNS and peripheral nervous system dysfunction 2 0 2
aEither nephrotic-range proteinuria or uncommon features.
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affected with the characteristic rash of Henoch–Scho¨nlein
syndrome. It is worthy of mention, however, that in cerebral
Henoch–Scho¨nlein syndrome CNS vasculitis sometimes precedes
or follows the rash. On the other side, clinicians must remember
that severe arterial hypertension and vasculitides associated with
IgG ANCAs, primary central nervous system vasculitis, Behc¸et
disease, Takayasu disease, Kawasaki disease, polyarteritis
nodosa or cryoglobulinaemic vasculitis [59, 60, 70–77] are possible
causes of both peripheral vasculitic neuropathy or CNS vasculitis,
whose presentation may often mimic or overlap with Henoch–
Scho¨nlein syndrome (Table 4). SLE, SSc, AS, juvenile idiopathic
arthritis, anti-phospholipid syndrome, sarcoidosis, familial
Mediterranean fever, CINCA syndrome (i.e. chronic infantile,
neurological, cutaneous and articular syndrome) and a number
of both non-opportunistic and opportunistic infections may also
mimic cerebral vasculitis [72, 78–81]. Furthermore, CNS or per-
ipheral nervous system adverse effects have been sometimes linked
with drugs used in the management of the aforementioned condi-
tions [72].
In patients with suspected CNS or peripheral nervous system
Henoch–Scho¨nlein syndrome, history and clinical presentation
are strongly variable. As a consequence, a strictly standardized
diagnostic work up is not advised. Nonetheless, considering that
‘non-Henoch–Scho¨nlein vasculitides’ affect the nervous system
more frequently than Henoch–Scho¨nlein syndrome, we urge test-
ing for aPL, ANA and IgG ANCAs in all cases. Furthermore,
considering the possible confusion with other vasculitides and the
role of IgA tissue deposits in Henoch–Scho¨nlein syndrome, the
detection of IgA in tissue-like skin or kidney appears imperative
in most cases. Neuroimaging is crucial to the diagnostic assess-
ment of suspected cerebral vasculitides: although catheter
angiography remains the gold standard, in clinical practice MRI
is usually the study of choice [5, 66].
Management
Controlled trials with significant and homogeneous case numbers
are not feasible with very rare and heterogeneous diseases such as
nervous system dysfunction in Henoch–Scho¨nlein syndrome [82].
With these limitations in mind, the data of the present review
prompt us to suggest the following management.
CNS. Like in adults with stroke, the initial management of
patients with suspected cerebral Henoch–Scho¨nlein syndrome
includes control of arterial hypertension, seizures and repair of
disordered hemostasis [83, 84]. In patients with intracerebral
haemorrhage, the indications for surgery are controversial and
vary with the site and the size of the bleed. Like in severe
Henoch–Scho¨nlein glomerulonephritis [85, 86], combined therapy
with corticoids and cyclophosphamide is appropriate in a patient
with relevant ischaemic cerebral lesions and Henoch–Scho¨nlein
syndrome. Anti-coagulation is advised in patients with secondary
anti-phospholipid syndrome [79].
Peripheral or cranial nervous system. Corticoids and cyclo-
phosphamide are not advised for Henoch–Scho¨nlein patients
with a peripheral or a cranial neuropathy, considering that these
conditions mostly tend to full spontaneous recovery. In Henoch–
Scho¨nlein purpura complicated by Guillain–Barre´ syndrome,
management with intravenous immune globulin (or plasma
exchange) is, like in the classical form of this polyneuropathy,
recommended [87].
In conclusion, the present systematic review helps clinicians
in the management of Henoch–Scho¨nlein patients with signs of
nervous system dysfunction.
Rheumatology key messages
 In Henoch–Scho¨nlein syndrome, relevant neurological disease is
rare but produces substantial morbidity and mortality.
 CNS dysfunction results from a vascular obstruction, from an
intracerebral haemorrhage or from severe hypertension.
 Peripheral nervous system dysfunction presents as polyneuro-
pathy, mononeuropathy or mononeuropathy multiplex.
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